M13Tx is a biotechnology company developing a phage-derived particle (PDP) gene delivery platform to address key limitations in the current gene therapy landscape. PDPs offer durable therapeutic efficacy via repeat administration, enable tissue-specific targeting, support massively scalable manufacturing, and can package any full-length human gene as a therapeutic (>20 kb). M13Tx's mission is to deliver any therapeutic gene to any target cell.